Hepatitus C is a closely related family of viral liver diseases composed of several subtypes (genotypes). According to the Centers for Disease Control, most patients infected with HCV develop chronic infections. Most of these develop some degree of chronic liver disease. Fewer than 20% of people with chronic HCV will develop cirrhosis of the liver. Fewer than 5% will end up dying of cirrhosis or liver cancer caused by the virus.

The FDA grants priority review status to drug candidates that may offer major advancements in treatment over existing options. The FDA has set a target review date of Dec. 8 under the Prescription Drug User Fee Act.

Gilead proposes the use of sofosbuvir and ribavirin, or RBV, as an all-oral therapy for genotype 2 and 3 HCV infection, and the use of sofosbuvir with RBV and pegylated interferon for patients who have never been treated for genotype 1, 4, 5, or 6 infections in the past.

Author

I like things that go "boom." Sonic or otherwise, that means I tend to gravitate towards defense and aerospace stocks. But to tell the truth, over the course of a dozen years writing for The Motley Fool, I have covered -- and continue to cover -- everything from retailers to consumer goods stocks, and from tech to banks to insurers as well. Follow me on Twitter or Facebook for the most important developments in defense & aerospace news, and other great stories besides.
Follow @richsmithfool